Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Primary prevention ICD: About one-fifth of the so-called SCD-HeFT population, heart failure patients indicated for a primary prevention implantable defibrillator, do not benefit from ICD therapy because their heart failure is too advanced, according to the results of a study by Wayne C. Levy, M.D., University of Washington, et al. that appears in the Sept. 8 issue of Circulation. The study analyzed data from 2,521 patients in the SCD-HeFT trial, the 2005 study that found that ICD therapy reduces overall mortality by 23% in patients with advanced heart failure and low ventricular ejection fraction. Using the Seattle Heart Failure Model, a prediction model based on routinely collected clinical variables, Levy et al. categorized the patients into five risk quintiles based on their predicted all-cause mortality with standard therapy. The study found that patients in the highest risk quintile had a slightly higher risk of mortality with an ICD than without it
You may also be interested in...
Edwards Looks To Smaller-Diameter Transcatheter Valve In 2010
Edwards Lifesciences hopes to overcome one of its biggest competitive disadvantages in the European transcatheter valve market early next year with the planned launch of a smaller-profile product
FDA, Cardiac Safety Research Consortium To Develop AF Ablation Registry
A consortium of academics, manufacturers and government agencies plans to launch a national atrial fibrillation ablation registry, based on input from a variety of stakeholders at a meeting April 27 and 28 at FDA's White Oak, Md., headquarters
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”